Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy
Author(s) -
María Dolores Sánchez-Niño,
Ana B. Sanz,
Susana Carrasco,
Moin A. Saleem,
Peter W. Mathieson,
José Manuel Valdivielso,
Marta RuizOrtega,
J. Egido,
Alberto Ortíz
Publication year - 2010
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfq306
Subject(s) - podocyte , fabry disease , endocrinology , medicine , calcitriol receptor , diabetic nephropathy , nephropathy , kidney , vitamin d and neurology , diabetes mellitus , proteinuria , disease
Transforming growth factor-β1 (TGF-β1) and the macrophage inhibitory factor receptor CD74 link the metabolic disorder with tissue injury in diabetic nephropathy. Fabry disease is an X-linked lysosomal glycosphingolipid storage disorder resulting from a deficient activity of α-galactosidase A that leads to proteinuric renal injury. However, the link between the metabolic abnormality and renal injury is poorly characterized. Globotriaosylsphingosine (lyso-Gb3) was recently identified as a bioactive molecule accumulating in Fabry disease. We hypothesized that lyso-Gb3 could modulate the release of secondary mediators of injury in glomerular podocytes and that recently described nephroprotective actions of vitamin D receptor activation in diabetic nephropathy may apply to lyso-Gb3.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom